Advertisement
A vs DHR
Which Stock Would AI Choose? Agilent Technologies (A) vs. Danaher (DHR) Stock Comparison
Key Takeaways
- Agilent Technologies (A) has delivered stronger recent momentum, with approximately 15-19% gains over the past month compared to more modest advances for Danaher (DHR).
- Both companies operate in the life sciences and diagnostics sector, but Agilent focuses on analytical instruments and measurement solutions while Danaher emphasizes broader healthcare platforms including bioprocessing.
- Agilent (A) trades near multi-month highs with year-to-date returns exceeding 17%, outpacing Danaher (DHR)’s approximately 4% YTD performance through late August 2026.
- Danaher (DHR) reported second-quarter results in July 2026 with earnings growth, though earlier market reactions highlighted challenges in bioprocessing demand recovery.
- Agilent (A) approaches its third-quarter earnings release on August 26, 2026, with analyst expectations centered on continued revenue expansion.
- Sector exposure and recent price stability position Agilent (A) with relatively consistent trend characteristics versus Danaher (DHR)’s more variable short-term movements.
Introduction
Agilent Technologies (A) and Danaher (DHR) represent two established players in the life sciences and healthcare technology space, making them natural subjects for side-by-side evaluation. Investors and traders seeking exposure to analytical instruments, diagnostics, and bioprocessing often weigh these names when assessing sector allocation. This comparison examines recent price behavior, business fundamentals, and relative positioning to help market participants understand key differences. The analysis draws on observable market data and company developments over recent weeks, providing context relevant for both active traders monitoring momentum and longer-term investors evaluating competitive dynamics within the broader healthcare equipment landscape.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies (A) provides analytical instruments, software, and services primarily for life sciences, applied markets, and diagnostics. In recent market activity, the stock has exhibited notable strength, climbing to levels near $159 as of August 21, 2026, with gains of roughly 15-19% over the preceding month and year-to-date returns around 17.55%. Performance has been supported by steady demand for its measurement solutions and positive revenue trends, including double-digit year-over-year growth reported in prior quarters. Sentiment has benefited from the company’s positioning ahead of its third-quarter earnings release scheduled for August 26, 2026, where analysts project continued expansion. Broader sector tailwinds in life sciences tools have contributed to the upward price trajectory observed in recent weeks.
Danaher (DHR) Overview and Recent Performance
Danaher (DHR) operates across life sciences, diagnostics, and environmental solutions, with significant exposure to bioprocessing and healthcare platforms. As of August 21, 2026, the stock traded near $219, reflecting year-to-date returns of approximately 4% amid more tempered market response. Second-quarter 2026 results, released in July, showed earnings growth on a continuing-operations basis, though earlier reactions to bioprocessing shipment timing influenced short-term sentiment. Recent weeks have seen modest recovery, with the share price demonstrating resilience within a wider trading range. Market positioning reflects ongoing focus on demand normalization in key segments, resulting in comparatively stable but less pronounced momentum versus broader sector peers during the period.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section that highlights select AI trading bots from its extensive library of hundreds of automated strategies. These bots cover thousands of tickers across equities, with only those demonstrating strong alignment to prevailing market conditions, consistent performance metrics, and suitable risk profiles earning placement in the trending roster. Available bots span diverse trading styles, timeframes, and statistical profiles, including ranges of win rates, drawdowns, and return characteristics that vary by strategy. This selection process allows users to review real-time suitability for current environments. Visit the Trending AI Robots page to explore active options and their detailed statistics.
Head-to-Head Comparison
Agilent Technologies (A) and Danaher (DHR) share life-sciences sector exposure yet differ in business model emphasis: Agilent centers on precision measurement and analytical tools, while Danaher encompasses wider platforms including bioprocessing and diagnostics. Recent momentum favors Agilent (A), which has posted stronger percentage gains and more consistent upward price action over recent weeks. Danaher (DHR) offers broader diversification across healthcare segments but has faced greater variability tied to bioprocessing cycles. Risk factors include Agilent’s (A) concentration in instrument demand cycles and Danaher’s (DHR) sensitivity to capital spending in life sciences. Market sentiment reflects Agilent’s (A) relatively firmer near-term positioning, whereas Danaher (DHR) trades at a valuation that incorporates longer recovery expectations. Trade-offs center on growth consistency versus portfolio breadth.
Tickeron AI Verdict
Based on observable factors including trend consistency, relative price stability, and recent momentum signals, Tickeron’s AI models currently indicate a probabilistic preference toward Agilent Technologies (A). The stock’s stronger short-term performance alignment and positioning ahead of earnings provide measurable edges in trend and catalyst visibility compared with Danaher (DHR)’s more measured recovery profile. This assessment remains probabilistic and subject to evolving market data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and DHR is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green whileDHR’s FA Score has 1 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- DHR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 4 TA indicator(s) are bullish while DHR’s TA Score has 2 bullish TA indicator(s).
- A’s TA Score: 4 bullish, 5 bearish.
- DHR’s TA Score: 2 bullish, 6 bearish.
Price Growth
A (@Medical Specialties) experienced а -2.38% price change this week, while DHR (@Medical Specialties) price change was -2.53% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.82%. For the same industry, the average monthly price growth was +8.64%, and the average quarterly price growth was +32.15%.
Reported Earning Dates
A is expected to report earnings on Nov 30, 2026.
DHR is expected to report earnings on Oct 27, 2026.
Industries' Descriptions
@Medical Specialties (+0.82% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| A | DHR | A / DHR | |
| Capitalization | 42.7B | 148B | 29% |
| EBITDA | 1.96B | 7.59B | 26% |
| Gain YTD | 11.927 | -7.918 | -151% |
| P/E Ratio | 29.86 | 37.42 | 80% |
| Revenue | 7.23B | 25.1B | 29% |
| Total Cash | 1.81B | 4.35B | 42% |
| Total Debt | 3.36B | 26.6B | 13% |
A | DHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 97 | 100 | |
SMR RATING 1..100 | 44 | 76 | |
PRICE GROWTH RATING 1..100 | 23 | 35 | |
P/E GROWTH RATING 1..100 | 40 | 60 | |
SEASONALITY SCORE 1..100 | 20 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (8) in the Medical Specialties industry is in the same range as A (11) in the Biotechnology industry. This means that DHR’s stock grew similarly to A’s over the last 12 months.
A's Profit vs Risk Rating (97) in the Biotechnology industry is in the same range as DHR (100) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is in the same range as DHR (76) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
A's Price Growth Rating (23) in the Biotechnology industry is in the same range as DHR (35) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
A's P/E Growth Rating (40) in the Biotechnology industry is in the same range as DHR (60) in the Medical Specialties industry. This means that A’s stock grew similarly to DHR’s over the last 12 months.
| A | DHR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 81% | 1 day ago 43% |
| Stochastic ODDS (%) | 1 day ago 56% | 1 day ago 61% |
| Momentum ODDS (%) | 1 day ago 66% | 1 day ago 55% |
| MACD ODDS (%) | 1 day ago 67% | 1 day ago 67% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 63% |
| TrendMonth ODDS (%) | 1 day ago 60% | 1 day ago 57% |
| Advances ODDS (%) | 8 days ago 60% | 7 days ago 54% |
| Declines ODDS (%) | 3 days ago 63% | 3 days ago 61% |
| BollingerBands ODDS (%) | 1 day ago 68% | 1 day ago 57% |
| Aroon ODDS (%) | 1 day ago 64% | 1 day ago 57% |
Advertisement